Parasitology Research

, Volume 107, Issue 6, pp 1429–1434 | Cite as

Silymarin treatment reduces granuloma and hepatic fibrosis in experimental schistosomiasis

  • Hílton Antonio Mata-Santos
  • Fabiana Gonçalves Lino
  • Carolina Carneiro Rocha
  • Claudia Neto Paiva
  • Morgana Teixeira Lima Castelo Branco
  • Alexandre dos Santos Pyrrho
Original Paper


The schistosomiasis is a parasitic infection with relevant social impact and an important health problem in many countries around world. The pathology of this infection is characterized by a granulomatous reaction around parasite eggs and by hepatic fibrosis. Silymarin, a complex compound isolated from Silybum marianum (L.) Gaertner, have been described as hepatoprotective, antioxidant, antifibrotic, immunomodulator, and anti-neoplastic agent. Some of these capacities could potentially protect against pathology in schistosomiasis. Herein, we evaluated the effects of silymarin on parasite burden, granuloma sizes, and liver fibrosis, which are associated with severity and morbidity of this disease. BALB/c mice treated intraperitoneally with 10, 20, or 25 doses of silymarin (10 mg kg−1) suspended in carboxymethylcellulose were analyzed at 55 days post-infection. Silymarin (1) did not affect parasite oviposition capacity; (2) reduced granulomatous peri-ovular reaction in the liver, and (3) decreased hepatic fibrosis in this infection. Taken together, these data suggest that treatment with silymarin at acute phase of schistosomiasis may result in a mild course of murine schistosomiasis and can be a promising complementary treatment reverting sequelae of this infection.



This work was supported by FAPERJ, CNPq, and FAF/FECD/OncoII. The authors are grateful to Laboratório de Malacologia (FIOCRUZ-RJ) for the S. mansoni cercariae.


  1. Agarwal R (2000) Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 60:1051–1059CrossRefPubMedGoogle Scholar
  2. Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D (1997) Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26:643–649CrossRefPubMedGoogle Scholar
  3. Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP (2009) Immunopathogenesis of human schistosomiasis. Parasite Immunol 31:163–176CrossRefPubMedGoogle Scholar
  4. Channabasavaraj KP, Badami S, Bhojraj S (2008) Hepatoprotective and antioxidant activity of methanol extract of Ficus glomerata. J Nat Med 62:379–383CrossRefPubMedGoogle Scholar
  5. Cheever AW (1968) Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues. Bull World Health Organ 39:328–331PubMedGoogle Scholar
  6. Cheever AW, Duvall RH, Hallack TA Jr, Minker RG, Malley JD, Malley KG (1987) Variation of hepatic fibrosis and granuloma size among mouse strains infected with Schistosoma mansoni. Am J Trop Med Hyg 37:85–97PubMedGoogle Scholar
  7. Chesney J, Metz C, Stavitsky AB, Bacher M, Bucala R (1998) Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol 160:419–425PubMedGoogle Scholar
  8. Cho JY, Kim PS, Park J, Yoo ES, Baik KU, Kim YK, Park MH (2000) Inhibitor of tumor necrosis factor- alpha production in lipopolysaccharide-stimulated RAW264.7 cells from Amorpha fruticosa. J Ethnopharmacol 70:127–133CrossRefPubMedGoogle Scholar
  9. Dehmlow C, Erhard J, de Groot H (1996) Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23:749–754CrossRefPubMedGoogle Scholar
  10. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN (2000) Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol 164:2585–2591PubMedGoogle Scholar
  11. Fanning MM, Peters PA, Davis RS, Kazura JW, Mahmoud AA (1981) Immunopathology of murine infection with Schistosoma mansoni: relationship of genetic background to hepatosplenic disease and modulation. J Infect Dis 144:148–153PubMedGoogle Scholar
  12. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schoniger-Hekele M, Holzmann H, Steindl-Munda P (2008) Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 135:1561–1567CrossRefPubMedGoogle Scholar
  13. Gebhardt R (2002) Oxidative stress, plant-derived antioxidants and liver fibrosis. Planta Med 68:289–296CrossRefPubMedGoogle Scholar
  14. Gharagozloo M, Velardi E, Bruscoli S, Agostini M, Di Sante M, Donato V, Amirghofran Z, Riccardi C (2010) Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production. Pharmacol Res 61(5):405–409CrossRefPubMedGoogle Scholar
  15. He Q, Osuchowski MF, Johnson VJ, Sharma RP (2002) Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: I induction of transforming growth factor beta1 and c-myc in liver with marginal effects on other genes. Planta Med 68:676–679CrossRefPubMedGoogle Scholar
  16. Henderson GS, Nix NA, Montesano MA, Gold D, Freeman GL Jr, McCurley TL, Colley DG (1993) Two distinct pathological syndromes in male CBA/J inbred mice with chronic Schistosoma mansoni infections. Am J Pathol 142:703–714PubMedGoogle Scholar
  17. Hoffmann KF, Cheever AW, Wynn TA (2000) IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol 164:6406–6416PubMedGoogle Scholar
  18. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, Savioli L (2007) Control of neglected tropical diseases. N Engl J Med 357:1018–1027CrossRefPubMedGoogle Scholar
  19. Huber A, Thongphasuk P, Erben G, Lehmann WD, Tuma S, Stremmel W, Chamulitrat W (2008) Significantly greater antioxidant anticancer activities of 2, 3-dehydrosilybin than silybin. Biochim Biophys Acta 1780:837–847PubMedGoogle Scholar
  20. Ibrahim R, Nagy F, Aly E, Mohamed A, EL-Assal F, El-Amir A (2010) Effect of treatment with antifibrotic drugs in combination with PZQ in immunized schistosoma mansoni infected murine model. J Am Sci 6:208–216Google Scholar
  21. Jia JD, Bauer M, Cho JJ, Ruehl M, Milani S, Boigk G, Riecken EO, Schuppan D (2001) Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 35:392–398CrossRefPubMedGoogle Scholar
  22. Johnson VJ, Osuchowski MF, He Q, Sharma RP (2002) Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: II. alterations in thymic differentiation correlate with changes in c-myc gene expression. Planta Med 68:961–965CrossRefPubMedGoogle Scholar
  23. Johnson VJ, He Q, Osuchowski MF, Sharma RP (2003) Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Med 69:44–49CrossRefPubMedGoogle Scholar
  24. Kang JS, Jeon YJ, Park SK, Yang KH, Kim HM (2004) Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1beta and prostaglandin E2 synthesis by silymarin. Biochem Pharmacol 67:175–181CrossRefPubMedGoogle Scholar
  25. Lee DG, Kim HK, Park Y, Park SC, Woo ER, Jeong HG, Hahm KS (2003) Gram-positive bacteria specific properties of silybin derived from Silybum marianum. Arch Pharm Res 26:597–600CrossRefPubMedGoogle Scholar
  26. Lenzi HL, Kimmel E, Schechtman H, Pelajo-Machado M, Romanha WS, Pacheco RG, Mariano M, Lenzi JA (1998) Histoarchitecture of schistosomal granuloma development and involution: morphogenetic and biomechanical approaches. Mem Inst Oswaldo Cruz 93(Suppl 1):141–151PubMedGoogle Scholar
  27. Lin YL, Hsu YC, Chiu YT, Huang YT (2008) Antifibrotic effects of a herbal combination regimen on hepatic fibrotic rats. Phytother Res 22:69–76CrossRefPubMedGoogle Scholar
  28. Mehlhorn H, Frenkel JK, Andrews P, Thomas H (1982) Light and electron microscopic studies on Schistosoma mansoni Granulomas of mouse livers following treatment with praziquantel. Tropenmed Parasitol 33:229–239PubMedGoogle Scholar
  29. Pearce EJ, MacDonald AS (2002) The immunobiology of schistosomiasis. Nat Rev Immunol 2:499–511CrossRefPubMedGoogle Scholar
  30. Pyrrho AS, Ramos JA, Neto RM, Silva CS, Lenzi HL, Takiya CM, Gattass CR (2002) Dexamethasone, a drug for attenuation of Schistosoma mansoni infection morbidity. Antimicrob Agents Chemother 46:3490–3498CrossRefGoogle Scholar
  31. Pyrrho AS, Lenzi HL, Ramos JA, Moura-Neto R, Cachem FC, Santos Da Silva C, Takiya CM, Gattass CR (2004) Dexamethasone treatment improves morphological and hematological parameters in chronic experimental schistosomiasis. Parasitol Res 92:478–483CrossRefPubMedGoogle Scholar
  32. Ramasamy K, Agarwal R (2008) Multitargeted therapy of cancer by silymarin. Cancer Lett 269:352–362CrossRefPubMedGoogle Scholar
  33. Ross AG, Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, schMcManus DP (2002) Schistosomiasis. N Engl J Med 346:1212–1220CrossRefPubMedGoogle Scholar
  34. Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G (2003) Silibinin protects mice from T cell-dependent liver injury. J Hepatol 39:333–340CrossRefPubMedGoogle Scholar
  35. Stegemann H, Stalder K (1967) Determination of hydroxyproline. Clin Chim Acta 18:267–273CrossRefPubMedGoogle Scholar
  36. Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C, Pinzani M (2009) Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol 50:1102–1111CrossRefPubMedGoogle Scholar
  37. Tyagi A, Singh RP, Ramasamy K, Raina K, Redente EF, Dwyer-Nield LD, Radcliffe RA, Malkinson AM, Agarwal R (2009) Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila Pa) 2:74–83Google Scholar
  38. Warren KS, Domingo EO, Cowan RB (1967) Granuloma formation around schistosome eggs as a manifestation of delayed hypersensitivity. Am J Pathol 51:735–756PubMedGoogle Scholar
  39. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, Wynn TA (2010) Bleomycin and IL-1{beta}-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 207:535–552CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Hílton Antonio Mata-Santos
    • 1
  • Fabiana Gonçalves Lino
    • 1
  • Carolina Carneiro Rocha
    • 1
  • Claudia Neto Paiva
    • 2
  • Morgana Teixeira Lima Castelo Branco
    • 3
  • Alexandre dos Santos Pyrrho
    • 1
  1. 1.Departamento de Análises Clínicas e Toxicológicas, Faculdade de FarmáciaUniversidade Federal do Rio de Janeiro (UFRJ)Rio de JaneiroBrazil
  2. 2.Departamento de Imunologia, Instituto de Microbiologia Prof. Paulo de GóesUFRJRio de JaneiroBrazil
  3. 3.Programa de Pesquisa em Glicobiologia, Instituto de Ciências BiomédicasUFRJRio de JaneiroBrazil

Personalised recommendations